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Introduction
Appropriate stimulation of the immune system with immune checkpoint inhibitors (CPIs) may cure patients with metastatic melanoma (MM) and other cancers. However, almost half of the patients with MM, and the vast majority of patients with all other types of solid cancers, do not derive any, or only a transient benefit from current CPIs, including anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD)-1. Thus, there is a pressing need to develop effective treatments, especially in BRAF wild-type MM where no other valid treatment alternatives exist for patients who progress following therapy with CPIs.
Resistance to CPIs is associated with the absence or low level of a variety of biomarkers including mutational load, IFNc gene signature and an overall lower level of immune activation in the tumor microenvironment (TME) [1] . Thus, CPI-resistant disease is thought to be largely associated with 'immunologically ignorant' tumors [1] . However, the functionality of immune responses in the TME of CPI-resistant disease remains uncharacterized.
Infusion of in vitro expanded autologous TILs via adoptive cell transfer (ACT) has consistently shown response rates of around 40%-50% in patients with anti-PD-1 naive (i.e. not previously exposed to anti-PD-1) MM [2] . However, the technical complexity and high toxicity of this treatment does not warrant its application in a first-line setting. On the basis of previous biomarker studies, patient populations with CPI-resistant MM may be more likely to present with tumors lacking sufficient major histocompatibility complex (MHC) class I antigen processing and presentation [3] . Thus, stimulation of alternative pathways to increase class I antigen processing and presentation machinery (APM) may improve the outcome of patients with CPI-resistant disease. Overall, further investigations on the outcome of patients treated with ACT following disease progression during CPIs eller CPI therapy are highly warranted.
With this study, we have begun to address these issues. First, we characterized the immune responses of TILs in CPI-resistant MM. Second, we assessed the clinical outcomes of patients with CPI-resistant MM in a phase I/II clinical trial of TIL-based ACT combined with pegIFNa2b. IFNa may increase antigen presentation [4] , polarize lymphocytes toward the pro-inflammatory Th1 phenotype [5] and upregulate the class I APM-potentially leading to improved immune recognition.
Materials and methods

Patient samples
All samples were obtained from patients undergoing tumor resection or baseline core-biopsy for enrolment in a clinical trial. In the TIL-based ACT trial, patients were enrolled in the protocol in a two-step enrolment process, as described previously [6] . Written informed consent was provided by all patients enrolled. Procedures were conducted in accordance with the Helsinki Declaration and Good Clinical Practice (GCP), which was monitored by the GCP-unit, Copenhagen, Denmark. All samples were obtained from patients who were treated with pembrolizumab (anti-PD-1) and, where indicated, ipilimumab (anti-CTLA-4).
TILs, autologous tumor cells and assays for antitumor reactivity
The TIL products were generated in vitro in two expansion steps; the initial expansion to obtain 'minimally expanded' or 'young TIL' and the rapid expansion (REP) to obtain REP TILs, described in detail in the supplementary Methods, available at Annals of Oncology online. Young TILs or REP TILs were used for all analyses. Autologous fresh tumor digests (FTDs) and short-term cultured tumor cell lines (TCLs) were established using the same tumor lesion from which the TILs were generated; MHC class I expression on TCLs was evaluated with flow cytometry; in vitro expanded TILs were tested for recognition of autologous short-term-cultured TCLs or autologous FTDs in co-culture assays. All these procedures were conducted as described previously [7] . A detailed description of antitumor reactivity assays is provided in supplementary Methods, available at Annals of Oncology online.
Histology
An additional portion of the tumor lesion removed for TIL manufacturing was available from 12 patients. The presence of CD8 þ TILs in situ was evaluated within two compartments of the tumor: (i) stromal TILs (sTILs) were present when CD8 þ T cells represented !5% of the cells in the stroma between tumor nests and (ii) intratumoral TILs (iTILs) were present when !5% of the cells within tumor nests, infiltrating between tumor cells were CD8 þ T cells. Combining the observations for each specimen resulted in the identification of three patterns of TIL localization: (A) both sTILs and iTILs, (B) sTILs but no iTILs and (C) no TILs (neither sTILs of iTILs) or TILs only in the Tumor-margin or periphery. A detailed description of sample preparation is provided in the supplementary Methods, available at Annals of Oncology online.
Clinical trial design
The clinical phase I/II trial was conducted at Center for Cancer Immune Therapy (CCIT) and Department of Oncology, Herlev and Gentofte Hospital, Denmark (ClinicalTrials.gov Identifier: NCT02379195), and enrolled patients with MM who progressed on or following anti-PD-1. Study treatment consisted of lymphodepleting chemotherapy followed by pegIFNa2b, TILs and intravenous IL-2. Additional description of the trial design is provided in supplementary Methods, available at Annals of Oncology online. The treatment and monitoring schedule is described in detail in supplementary Figure S1 , available at Annals of Oncology online. The primary objective was to evaluate the safety and tolerability of the study treatment. Secondary objectives were to determine the overall response rate (ORR) by RECIST 1.1, progression-free survival (PFS), overall survival (OS) and immune responses.
Statistical analysis
PFS was defined as the time from TIL infusion until tumor progression or death. OS was defined as the time from TIL infusion until death. Patients alive at the date of data cut-off (2 August 2017) were censored. Statistical tests were conducted using a paired Wilcoxon signed rank test. Graphs and statistical tests were generated using Graphpad Prism 5.
Results
Immune recognition of anti-PD-1/CTLA-4-resistant melanoma
Biopsies from a total of 26 consecutive patients were collected. TILs were obtained from all samples (26/26, 100%). TCLs were generated from 16/26 samples (61%), and FTDs were available from 18/26 samples (69%). Only patients with either TCLs or FTDs (23/26, 88%) were analyzed. The majority of patients (17/ 23, 74%) had previously received monotherapy with anti-CTLA-4, and all were previously treated with anti-PD-1. Supplementary  Table S1 , available at Annals of Oncology online summarizes previous treatment with CPIs and the resulting clinical outcomes.
Immune recognition of autologous TCLs by CD8 þ TILs was observed in 15/16 samples (94%), while FTDs were recognized in 12/18 samples (67%) ( Figure 1A ). Overall, immune recognition of autologous tumor cells by CD8
þ TILs was observed in 18/23 samples (78%). The magnitude of responses varied widely, from 1.0% to 84% of all CD8
þ TILs (median 23.2%) ( Figure 1A ). Immune recognition of autologous TCLs by CD4
þ TILs was observed in 12/ 16 samples (75%), while FTDs were recognized in 11/18 samples (61%) ( Figure 1B ). Overall, immune recognition of autologous tumor cells was observed in 16/23 samples (70%). The magnitude of responses varied from 0.7% to 14% of all CD4
þ TILs (median 4.5%) ( Figure 1B ). Overall, tumor-specific T cell responses (either CD8 þ or CD4 þ ) were detected in 19/23 patients (83%). These numbers are largely superimposable to previous studies which we conducted on unselected populations of samples obtained from patients with MM who were anti-PD-1 naive [7] .
Localization of the immune infiltrates in CPIresistant melanoma CPI-resistant tumors are currently believed to be more likely to present with a 'immunologically ignorant' or 'non-inflamed' phenotype, characterized by the absence of immune infiltration [1] . However, our functional analyses demonstrated that tumorreactive T cells can be broadly isolated from tumor specimens of CPI-resistant MM. This apparent discrepancy urged us to investigate the localization of immune infiltrates in our cohort.
For patients with a high CD8 þ T cells response (fraction of tumor reactive CD8 þ T cells above 10%, n ¼ 7), the localization of the immune infiltrate was heterogeneous: 2/7 with pattern A, 3/7 with pattern B and 2/7 with pattern C (supplementary Table  S2 , available at Annals of Oncology online and Figure 1C-E) . Therefore, it appears that highly reactive CD8 þ T cells can infiltrate CPI-resistant tumors to various degrees. The heterogeneity of infiltration patterns suggests that multiple mechanisms of immune resistance to CPI exist. T cells infiltration of the TME was also detected in most patients with lower or no CD8 þ T cells responses (supplementary Table S2 , available at Annals of Oncology online). Of all 12 patient specimens analyzed, iTILs were observed in only three patients. Interestingly, among samples evaluated from patients treated in the phase I/II trial, only the two patients who obtained a confirmed clinical response (MM06 and MM12) had iTILs (supplementary Table S2 , available at Annals of Oncology online).
Effects of interferon-a on tumor-immune recognition
Patient populations with CPI-resistant MM may be more likely to present with tumors lacking sufficient MHC class I antigen processing and presentation [3] or IFNc signaling [8] . The ability of interferons to increase the immunogenicity of cancer cells prompted us to investigate whether IFNa could increase the recognition of whole tumor cells by autologous melanoma TILs in CPI-resistant MM.
Exposure of autologous TCLs to IFNa significantly increased both the expression of MHC class I on tumor cells (supplementary Figure S2A , available at Annals of Oncology online) as well as antitumor CD8
þ T cells responses (P ¼ 0.004) (supplementary Figure S2B , available at Annals of Oncology online). In contrast, IFNa did not increase CD4 þ T cell responses (P ¼ 0.5) (supplementary Figure S2C , available at Annals of Oncology online). These results confirmed previous observations indicating that interferons, including IFNa, can increase antitumor CD8 þ T cell responses in vitro. Overall, our data supported the hypothesis that pegIFNa2b may improve the clinical outcome of CPI-resistant MM patients after TIL-based ACT. Figure S3 , available at Annals of Oncology online. Percentage changes in target lesion size compared with baseline for the 11 assessable patients are shown in Figure 2A and B. Best objective responses of individual patients, according to RECIST 1.1, are illustrated in Figure 2C . The median PFS was 2.8 months and the median OS was 14 months. At data cut-off (2 August 2017), 4/12 patients (33%) were alive with a median follow-up of 14 months. Kaplan-Meier curves of PFS and OS are shown in Figure 2D and E. All patients experienced the anticipated Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 hematologic toxicities caused by chemotherapy and bone marrow function generally recovered within a few weeks after treatment. Non-hematologic adverse events are shown in supplementary Figure 2F . The characteristics of TIL infusion products are shown in supplementary Table S6 , available at Annals of Oncology online and additional description of TIL characteristics is provided in the supplementary Data, available at Annals of Oncology online.
Phase I/II clinical trial
Discussion
Current CPIs are believed to inhibit adaptive immune resistance, unleash pre-existing CD8 þ T cells within the TME, and thereby induce clinical responses [9] . Current evidence suggests that tumors with pre-existing immune responses [1] (otherwise referred as 'immunogenic' [10] , 'hot' [10] or 'inflamed' [11] tumors) respond better to treatment with CPI monotherapy [9, 12] . On the other hand, patients who do not respond to CPIs are largely believed to MM03  MM05  MM07  MM11  MM12  MM13  MM14  MM17  MM22  MM25  MM27  MM28  MM30  MM31  MM06  MM08  MM10  MM15  MM16  MM20  MM23   MM01  MM02  MM03  MM05  MM07  MM11  MM12  MM13  MM14  MM17  MM22  MM25  MM27  MM28  MM30  MM31  MM06  MM08  MM10  MM15  MM16  MM20  MM23 MM22 MM08 þ TILs in resected tumor specimens. Images of tumor tissue from representative patients after formalin-fixation and paraffin-embedding, immunohistochemistry staining for CD8 (upper panels) and corresponding hematoxylin/eosin staining (lower panels). The three histology patterns are described in Materials and methods. iTIL, intratumoral TIL; sTIL, stromal TIL; mTIL, marginal TIL.
have poorly immunogenic tumors with limited or absent T cell infiltration (also known as 'immune deserts' [1] , 'cold' [10] or 'noninflamed' tumors [11] ). No standard immunological treatments exist for patients with MM who have progressed to anti-CTLA-4 and anti-PD-1 therapy. Only recently, sporadic induction of tumor regression with other immune-activating agents was reported in PD-1-resistant MM, renal cell carcinoma and non-small-cell lung cancer [13] [14] [15] . Teng et al. [16] estimated the proportion of unselected melanomas with TIL infiltrates to be around 58% (38% TIL þ PD-L1 þ and 20% TIL þ PD-L1 -) and suggested that this would predict a better outcome of CPI treatment. Thus, one would expect that patients who progress on the above CPIs are strong members of the 'immune desert' category. In apparent contrast with these findings, we found that most tumors from a cohort with CPIresistant MM were infiltrated with tumor-reactive TILs. Tumorspecific immune responses were detected in 83% of patients, which is similar to the frequency of antitumor responses detected in in vitro expanded TILs in anti-PD-1 naive MM (in other studies 89% [7] , 81% [17] and 74% [18] ). The median percentage of tumor-reactive T cells recovered was 23% for CD8 þ and 4.5% for CD4 þ T cells, similar to a previous study enrolling anti-PD-1 naive patients (only REP TILs were used in the study, the median was 18% for CD8 þ and 4% for CD4 þ T cells [7] ). These data indicate that the 'immune desert' phenotype is rare in CPI-resistant MM [1] . Rather, although the nature of the TILs may to some extent reflect culture conditions and previous treatments may have contributed to induce intratumoral changes influencing these results, large numbers of endogenous antitumor T cells can be isolated frequently from the TME of most CPI-resistant MM tumors.
Hegde et al. [1] recently classified the immunity of tumors into three major histology subtypes: (i) 'preexisting immunity', highly inflamed tumors characterized by the presence of TILs; (ii) 'excluded infiltrate', intermediately inflamed tumors with stromal or peritumoral TIL localization; (iii) 'immunologically ignorant' or 'immune desert', with very limited or no infiltration of TILs. We found that patients with CPI-resistant MM and a high percentage of tumor-reactive CD8
þ TILs may display heterogeneous histology features, showing a continuum from TILinfiltrates only in the invasive margin, to their presence in the intratumoral stroma and within tumor areas. These findings suggest that the mechanisms leading to resistance to current CPIs are largely individual, so while in some patients, resistance may be associated with T cell exclusion [19] (phenotype B or C), in other patients other immunosuppressive factors of the TME, such as multiple additional checkpoints [10] (phenotype A) may play a major role. These data support biomarker-driven strategies to study the TME of individual patients with CPI-resistant melanoma to guide treatment strategies. Clinical trials using agents to improve T cell trafficking into tumor areas (specifically targeting phenotype B and C-e.g. bevacizumab [20] ) or to target additional immune checkpoints (specifically targeting phenotype A-e.g. relatlimab [13] ) are currently ongoing.
Having established that samples of CPI-resistant MM frequently contain highly potent tumor-reactive TILs, we investigated whether these immune responses could be reinvigorated and exploited for the treatment of CPI-resistant MM in a clinical TIL therapy trial. In preclinical proof-of-concept studies, we demonstrated that IFNa could improve tumor recognition of TILs obtained from this patient population. In addition, three recent phase I and II studies evaluated the combination of IFNa with anti-CTLA-4 antibodies or adoptive transfer of bloodderived T cells, with promising clinical efficacy and acceptable safety [21] [22] [23] . Here, we showed that the combination of pegIFNa2b with TIL-based ACT and an attenuated dose IL-2 regimen could induce tumor regression in this difficult-to-treat patient population, with 2 out of 11 objective responders. Treatment-related toxicities were manageable in a regular oncology ward. However, given the small sample size, we cannot conclude whether pegIFNa improved the efficacy of ACT with TILs, nor whether the response rates in CPI-resistant MM were lower than in anti-PD-1 naive MM (consistently reported at rates of around 40%-50% [2] ). Indeed, our efficacy results are consistent with three ACT studies enrolling small cohorts of patients with MM who progressed on or following anti-PD-1 (4 of 11 [24] , 4 of 14 [25] and 3 of 8 [26] with ORs). One ongoing study is investigating whether there is a difference in response rate between patients who have received prior anti-PD1 treatment to those who are anti-PD1 naive (clinicaltrials.gov identified: NCT01993719). In addition, in our study, the PFS was very short (2.8 months), in line with anti-PD-1 where after previous lines of treatment (Keynote-002) lower responses were observed as compared with first-line treatment (Keynote-006). Thus, it can be anticipated that novel strategies may be necessary to improve the outcome of patients with anti-CTLA-4 and anti-PD-1-resistant disease.
In conclusion, tumor-reactive TILs infiltrated the TME of most patients with CPI-resistant MM. It was possible to take therapeutic advantage of these TILs in a clinical trial although clinical response rates in this difficult patient population appeared low. The infiltration of the TME by tumor-reactive TILs in most patients with CPI-resistant melanoma warrants further investigation of immune escape mechanisms and testing of novel immune re-activation strategies.
